MDACC Study No:2006-0764 ( NCT No: NCT00428545)
Title:A Phase I Trial of Bevacizumab and Bortezomib in Patients with Advanced Malignancy
Principal Investigator:Gerald Falchook
Treatment Agent:Bevacizumab; Bortezomib
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of Avastin™ (bevacizumab) and Velcade™ (bortezomib) that can be given in
combination to patients with a metastatic or unresectable advanced malignancy.
The safety and effectiveness of this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers; Lymphoma; Myeloma; Solid Tumors
Phase of Study:Phase I
Treatment Agents:Bevacizumab
Treatment Location:Independent Multicenter Arrangements
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Days 1, 4, 8, and 11 every 21-days
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gerald Falchook
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults